特写特讯！小米汽车21.9万起售？官方辟谣：假的！

小米汽车21.9万起售？官方辟谣：假的！

2024年3月1日讯 近日，网传一张小米汽车的配置及价格表格，显示小米汽车基础款价格为21.9万元。对此，小米集团公关部总经理王化在微博发文辟谣称，该表格为假消息。

王化表示，“社群里面流传的一张图，配置搭配价格，看上去挺唬人的。这种造假成本极低，就一个表格截图……好在看到不少人都说一眼假，大家还是能分辨真假的。”

据了解，小米汽车预计将于2024年正式上市。 此前，小米曾多次表示，小米汽车将是一款高性能、智能化的电动汽车，并将在价格上具有竞争力。

以下是一些与本新闻相关的补充信息：

• 小米汽车是小米集团进军汽车行业的重要布局。
• 小米汽车的研发工作正在紧锣密鼓地进行中。
• 小米汽车的上市备受外界关注。

希望这篇新闻报道能够为您带来帮助。

以下是一些网友对此新闻的评论：

• “小米汽车终于要来了吗？期待！”
• “希望小米汽车的价格不要太贵。”
• “小米汽车的质量和性能怎么样？还有待观察。”
• “我对小米汽车的自动驾驶功能很感兴趣。”
• “希望小米汽车能够尽快上市。”

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.